

Chronic Lymphocytic Leukemia (CLL) Gene Expression and IgVH Mutational Status Testing Update

Effective Date: January 07, 2020

Effective January 07, 2020, Beaumont Laboratory will modify the Chronic Lymphocytic Leukemia (CLL) Gene Expression and IgVH Mutational Status test as outlined below.

The modified test will have the following advantages:

- The tested Chronic Lymphocytic Leukemia (CLL) IgHV Mutational Status will be accurately reflected in the test name.
 - LPL/ADAM29 Gene expression will no longer be reported.
- The testing will provide a prognostic result and interpretation in line with ERIC 2017 recommendations¹.
 - 1. Rosenquist R, et al. Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations. *Leukemia* (2017) 31, 1477-1481.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508071/>

NEW TEST INFORMATION:

Test Name: Chronic Lymphocytic Leukemia (CLL) IgHV Mutational Status
EPIC Code: LAB7815
SOFT Code: GIGHV

OLD TEST INFORMATION:

Test Name: Chronic Lymphocytic Leukemia (CLL) Gene Expression and IgVH Mutational Status
EPIC Code: LAB6380
SOFT Code: GCLLG

If you have questions, please contact Client Services (1-800-551-0488, option 5).

Laboratory Test Directory: <http://beaumontlaboratory.com/test-lab-directory>

Date submitted: December 18, 2019

Submitted by: Kausar Jabbar, MD
Medical Director, Molecular Pathology